ATNX Athenex Inc

Price (delayed)

$1.39

Market cap

$12.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.81

Enterprise value

$105.52M

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment ...

Highlights
The EPS has soared by 59% YoY and by 50% from the previous quarter
ATNX's net income is up by 48% year-on-year and by 40% since the previous quarter
The gross profit has grown by 27% since the previous quarter but it has declined by 18% year-on-year
The gross margin has contracted by 24% YoY but it has grown by 22% from the previous quarter
ATNX's equity has dropped by 126% since the previous quarter and by 113% year-on-year
The quick ratio has contracted by 36% from the previous quarter and by 36% YoY

Key stats

What are the main financial stats of ATNX
Market
Shares outstanding
8.66M
Market cap
$12.04M
Enterprise value
$105.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.03
Earnings
Revenue
$102.82M
EBIT
-$77.24M
EBITDA
-$74.92M
Free cash flow
-$75.43M
Per share
EPS
-$15.81
Free cash flow per share
-$11.53
Book value per share
-$0.83
Revenue per share
$15.72
TBVPS
$20.17
Balance sheet
Total assets
$204.06M
Total liabilities
$228.24M
Debt
$129.1M
Equity
-$6.51M
Working capital
$10.05M
Liquidity
Debt to equity
-19.84
Current ratio
1.09
Quick ratio
0.56
Net debt/EBITDA
-1.25
Margins
EBITDA margin
-72.9%
Gross margin
26%
Net margin
-100.6%
Operating margin
-68.1%
Efficiency
Return on assets
-46.4%
Return on equity
-606%
Return on invested capital
-52.2%
Return on capital employed
-86.6%
Return on sales
-75.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNX stock price

How has the Athenex stock price performed over time
Intraday
6.92%
1 week
-21.02%
1 month
-49.27%
1 year
-93.05%
YTD
-52.88%
QTD
-52.88%

Financial performance

How have Athenex's revenue and profit performed over time
Revenue
$102.82M
Gross profit
$26.7M
Operating income
-$70.01M
Net income
-$103.43M
Gross margin
26%
Net margin
-100.6%
The operating margin has surged by 57% year-on-year and by 46% since the previous quarter
The operating income has soared by 53% YoY and by 44% from the previous quarter
Athenex's net margin has soared by 52% YoY and by 43% from the previous quarter
ATNX's net income is up by 48% year-on-year and by 40% since the previous quarter

Growth

What is Athenex's growth rate over time

Valuation

What is Athenex stock price valuation
P/E
N/A
P/B
N/A
P/S
0.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.03
The EPS has soared by 59% YoY and by 50% from the previous quarter
ATNX's equity has dropped by 126% since the previous quarter and by 113% year-on-year
The stock's P/S is 99% below its 5-year quarterly average of 7.0 and 82% below its last 4 quarters average of 0.5
The revenue has increased by 8% YoY and by 4% from the previous quarter

Efficiency

How efficient is Athenex business performance
The ROS has soared by 62% YoY and by 51% from the previous quarter
ATNX's return on invested capital is up by 42% since the previous quarter and by 28% year-on-year
ATNX's ROA is up by 36% QoQ and by 18% YoY
Athenex's return on equity has decreased by 10% QoQ

Dividends

What is ATNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNX.

Financial health

How did Athenex financials performed over time
The total assets is 11% less than the total liabilities
The quick ratio has contracted by 36% from the previous quarter and by 36% YoY
Athenex's current ratio has decreased by 27% QoQ and by 22% YoY
ATNX's equity has dropped by 126% since the previous quarter and by 113% year-on-year
Athenex's debt has decreased by 13% YoY but it has increased by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.